Date of Report (Date of earliest event reported): May 19, 2026
TREACE MEDICAL CONCEPTS, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-40355
47-1052611
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
100 Palmetto Park Place
Ponte Vedra, Florida32081
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (904) 373-5940
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
TMCI
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07.Submission of Matters to a Vote of Security Holders.
At the 2026 Annual Meeting of Stockholders (the "Meeting") of Treace Medical Concepts, Inc. (the "Company") held on May 19, 2026, the stockholders of the Company voted on the following proposals, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 6, 2026. The results of voting on the three proposals, including final voting tabulations, are set forth below.
Proposal 1: Election of Directors.
The stockholders elected, by the votes indicated below, the following nominees to the Company’s Board of Directors to serve as Class II directors for a three-year term of office expiring at the 2029 annual meeting of stockholders or until their respective successors have been duly elected and qualified:
Name
For
Withheld
Broker Non-Vote
Lance A. Berry
33,804,407
820,723
13,516,432
Elizabeth S. Hanna
30,856,965
3,768,165
13,516,432
Jane E. Kiernan
33,587,226
1,037,904
13,516,432
Proposal 2: Advisory Vote on Executive Compensation.
By the vote stated below, the stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers:
For
Against
Abstain
Broker Non-Vote
32,785,505
1,724,383
115,242
13,516,432
Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm.
By the vote stated below, the stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
For
Against
Abstain
Broker Non-Vote
47,885,305
120,733
135,524
0
Item 9.01
Financial Statements and Exhibits.
Exhibit No.
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.